If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

Share Price is delayed by 15 minutes
Get Live Data
6.85    -0.60 (-8.45%)
Bid:
6.70
Ask:
7.00
Spread: 0.30 (4.478%)
Market Cap: £2.85m
FDBK Live PriceLast checked at - London Stock Exchange

Intraday Feedback Share Chart

Bleepa® achieves CE Mark

1 Jun 2020 07:00

RNS Number : 4523O
Feedback PLC
01 June 2020
 

Feedback plc

 

Bleepa® achieves CE Mark, raising the bar for medical communication platforms

 

CE mark confirms use of Bleepa as a Class 1 Medical Device

The Directors of Feedback believe Bleepa is the only communication platform to address the UK market that has met MDD certification requirements

 

London, 01 June 2020: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces that, in compliance with the Medical Device Directive ("MD Directive") and having met the stringent criteria associated with the manufacture of a medical device, it has affixed a CE Mark to Bleepa. Bleepa is Feedback's flagship imaging-based communication platform for clinicians to access medical grade images through smartphones, tablets and desktops.

 

All clinical communication platforms that display digital images of patients for the purpose of diagnosis are classed as medical devices under the MD Directive guidelines and require a CE mark. The Directors of Feedback believe that Bleepa is the only communication platform to address the UK market that has met MD Directive certification requirements.

 

The Directors also believe that having a CE mark is a major step forward for the Bleepa product since the use of a non-CE marked product inappropriately may put individual clinicians and Trusts at risk of civil claims for damages arising from misuse of that product. For this reason the Medicines & Healthcare products Regulatory Agency ("MHRA") advise that all providers only use appropriately CE marked devices.

 

Dr Tom Oakley, CEO of Feedback, commented:

 

"We believe that Bleepa is the future for communicating about patient care and is already changing the way in which clinicians discuss cases and process patients through the hospital system. The CE mark is an important milestone in its commercialisation and sets Feedback apart from other providers.

 

"Pennine Acute Hospitals NHS Trust and Royal Papworth Hospital NHS Foundation Trust are both demonstrating the value of using Bleepa across the hospital setting. This important regulatory milestone offers healthcare providers confidence in our product over other unregulated providers as we continue the roll-out of Bleepa in support of the NHS, both to support the fight against COVID-19 as well in day-to-day patient management."

 

Under MD Directive guidelines MedDev 2.1/6, any product that acts as an image viewer with functionality for diagnosis based on digital images may be classified as a medical device. Any communication platform being used by clinicians to display digital patient images as part of case discussion meets this stipulation and are classified as a medical device under the MD Directive. Under EU and UK law, CE marking is mandatory and manufacturers must ensure the product bears CE marking if such product comes under the scope of a directive requiring CE Marking.

 

Clinicians and hospitals are advised by the MHRA to use medical devices with a CE mark, as this shows the device has met the legal requirements for safety, quality and performance when it is used as the manufacturer instructs. The MHRA further advises that off-label use of a device, such as use of a device that does not carry an appropriate CE mark will be at such user's own risk and such person or their employer could become liable for civil claims for damages from injured patients or their families if something goes wrong with the device.

 

The Directors of Feedback ("the Directors") believe that Bleepa is the only communication platform combining imaging and instant messaging to address the UK market that has certified its compliance with the MD Directive and is therefore legally able to market itself as having image display capabilities. The CE Mark Technical File defines the use case for Bleepa and provides protection not only for the hospital Trust but also for the individual clinician using the app, which the Directors believe will make Bleepa the clinical communications tool of choice.

 

Dr Oakley added: "We believe that many NHS sites are unknowingly using uncertified tools and are therefore exposed to civil claims arising from use of those tools. Bleepa will enable Trusts to engage the digital communication revolution safely and securely within a regulated environment. Ensuring the roll out of a regulated communication platform should be a key priority for the NHS in its efforts to combat COVID-19 and beyond. Bleepa is now uniquely positioned to deliver against this need."

 

Real world feedback forms an essential component of CE accreditation and the deployment at Pennine Hospitals NHS Trust not only generated the required clinical feedback but additionally led to improvements in the product that have been incorporated into the CE marked version of Bleepa. The CE marked version of Bleepa will now be deployed at Royal Papworth Hospital as Feedback's second NHS site.

 

 

-Ends-

 

Enquiries:

 

Feedback plc

Tom Oakley, CEO

Lindsay Melvin, CFO

+44 (0)1954 718072

IR@fbk.com

 

 

Allenby Capital Limited (Nominated Adviser)

David Worlidge / Asha Chotai

+44 (0)20 3328 5656

 

 

Peterhouse Capital Limited (Joint Broker)

Lucy Williams / Duncan Vasey

+44 (0)20 7469 0936

 

 

Stanford Capital Partners Limited (Joint Broker)

Patrick Claridge / John Howes

+44 20 3815 8880

 

 

Instinctif Partners

Melanie Toyne-Sewell / Phillip Marriage

+44 (0)20 7457 2020

+44 7890 022 814

feedbackplc@instinctif.com

 

Notes to editors

 

About Bleepa

 

Bleepa provides instant and remote access to clinical grade medical images through a zero footprint application. The majority of patient cases require medical imaging which can be seamlessly shared to the entire clinical team through Bleepa. Cases can be discussed through its secure instant messaging and image annotation, allowing comments and treatment decisions to be communicated instantly between team members. Bleepa can be accessed from any internet connected device including phones, tablets, laptops and desktops; clinicians can use their own devices and therefore no additional hardware is required.

 

About Feedback plc - www.fbk.com

 

Feedback plc (AIM: FDBK) is a specialist medical imaging technology company providing innovative software and systems, through its fully-owned trading subsidiary, Feedback Medical Limited. Its products advance the work of radiologists, clinicians and medical researchers by improving workflows and giving unique insights into diseases, particularly cancer.

 

Feedback has launched Bleepa®, a new secure, encrypted medical communication app for clinicians accessible through smartphones, tablets and desktops that facilitates rapid clinical messaging and review of medical grade imaging for all members of a clinical team, directly from a hospital Picture Archiving and Communications System (PACS). For more information on Bleepa®, see www.bleepa.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCBRGDUCDXDGGB
Date   Source Headline
25th Feb 20114:04 pmRNSDirector/PDMR Shareholding
22nd Feb 20118:00 amRNSHalf Yearly Report
18th Feb 20114:16 pmRNSDirectorate Change
11th Feb 201111:58 amRNSDirectorate Change
29th Nov 201010:08 amRNSDirector/PDMR Shareholding
29th Oct 20107:00 amRNSFinal Results
29th Apr 20107:00 amRNSDirector/PDMR Shareholding
28th Apr 20107:00 amRNSDirector/PDMR Shareholding
24th Feb 20107:00 amRNSInterim Results
30th Oct 200911:30 amRNSFinal Results
12th Aug 20097:00 amRNSDirectorate Change
17th Feb 20097:00 amRNSHalf Yearly Report
8th Dec 20084:42 pmRNSDirectorate Change
19th Nov 20087:00 amRNSDirector/PDMR Shareholding
23rd Oct 20087:00 amRNSDirector/PDMR Shareholding
15th Oct 20084:59 pmRNSDirector/PDMR Shareholding
9th Oct 20087:00 amRNSFinal Results
2nd Jun 200812:37 pmRNSHolding(s) in Company
30th May 20085:38 pmRNSTotal Voting Rights
21st May 200811:45 amRNSResult of EGM
24th Apr 20087:55 amRNSProperty Purchase
4th Apr 20087:01 amRNSDirectorate Change
26th Mar 200810:06 amRNSDirectorate Change
28th Feb 20088:06 amRNSInterim Results
11th Feb 20089:21 amRNSUpdate on CVA
10th Jan 20087:00 amRNSDirectorate Change
10th Dec 20075:23 pmRNSCapital Reorganisation
10th Dec 20074:00 pmRNSCapital Reorganisation
13th Nov 20077:00 amRNSDirectorate Change
26th Oct 20073:45 pmRNSDirector/PDMR Shareholding
25th Oct 20071:13 pmRNSOffer Talks Terminated
17th Oct 20071:39 pmRNSStatement re Possible Offer
27th Sep 20077:01 amRNSFinal Results
16th Aug 20079:02 amRNSAIM Rule 26 Information
31st Jul 20073:45 pmRNSTotal Voting Rights
25th Jul 20078:26 amRNSDirectorate Change
20th Jul 20074:41 pmRNSDirector/PDMR Shareholding
18th Jul 20074:07 pmRNSHolding(s) in Company
17th Jul 20071:06 pmRNSHolding(s) in Company
9th Jul 20074:30 pmRNSHolding(s) in Company
5th Jul 200710:16 amRNSHolding(s) in Company
2nd Jul 20071:07 pmRNSResult of EGM
5th Jun 20077:02 amRNSIssue of Equity
2nd May 200711:03 amRNSHolding(s) in Company
30th Apr 200712:28 pmRNSTotal Voting Rights
30th Mar 200710:16 amRNSTotal Voting Rights
2nd Mar 20072:31 pmRNSIssue of Equity
7th Feb 20077:01 amRNSUpdate on Property Disposal
21st Dec 200611:29 amRNSTotal Voting Rights
19th Dec 20062:36 pmRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.